ErbB3-miRNA axis in tumor metastasis of erbB2-positive breast cancer

erbB2 阳性乳腺癌肿瘤转移中的 ErbB3-miRNA 轴

基本信息

  • 批准号:
    9342732
  • 负责人:
  • 金额:
    $ 35.05万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-09-01 至 2021-08-31
  • 项目状态:
    已结题

项目摘要

Elevated expression of erbB3 receptor correlates with increased distant metastasis of breast cancers with amplification and/or overexpression of erbB2 (HER2/neu), which occur in approximately 25-30% of invasive breast cancers and are significantly associated with a worse prognosis in breast cancer patients. The erbB3 receptor frequently co-expresses and interacts with erbB2 in breast cancer to activate the oncogenic signaling, especially the PI-3K/Akt pathway and Src kinase. ErbB3 serves as a co-receptor of erbB2 and plays a critical role in the development of erbB2-overexpressing (erbB2+) breast cancer. Our recent data reveal that overexpression of erbB3 decreases, and inhibition of erbB3 signaling with an erbB3 specific shRNA, an anti-erbB3 blocking antibody (Ab), or an Akt inhibitor increases the levels of miR-203 and miR- 542-3p in erbB2+ breast cancer cells. Interestingly, both miR-203 and miR-542-3p have been identified as tumor suppressive miRNAs, and are frequently downregulated due to promoter methylation in various human cancers, including breast cancer. Bioinformatics analysis suggests that miR-203 and/or miR-542-3p target several critical genes, including Survivin, ZEB1, ZEB2, Snail1, and/or Slug, responsible for drug resistance, epithelial-mesenchymal transition (EMT), and tumor metastasis. We also discover an enhanced expression of ZEB1, Snail1, Slug, and Vimentin upon ectopic expression of erbB3 in erbB2+ breast cancer cells. Thus, we hypothesize that activation of erbB3 signaling promotes erbB2+ breast cancer metastasis via epigenetic silencing of the tumor suppressive miR-203/miR-542-3p and effective inhibition of erbB3 will significantly suppress metastasis via induction of miR-203/miR-542-3p. We intend to define miR- 203 and miR-542-3p as the key downstream mediators of erbB3 signaling to enhance metastatic potential of erbB2+ breast cancer cells by upregulating the EMT markers; and identify novel strategy/agents inhibiting erbB3 to prevent or attenuate erbB2+ breast cancer metastasis via induction of miR-203/miR-542-3p.
erbB 3受体表达升高与乳腺癌远处转移增加相关, erbB 2(HER 2/neu)扩增和/或过表达,发生在大约25-30%的侵袭性肿瘤中。 与乳腺癌患者的预后不良显著相关。erbB3 受体在乳腺癌中经常与erbB 2共表达并相互作用,以激活癌基因 信号转导,尤其是PI-3 K/Akt通路和Src激酶。ErbB 3作为erbB 2的共受体, 在erbB 2过表达(erbB 2+)乳腺癌的发展中起着关键作用。我们最近的数据 显示erbB 3的过度表达减少,并且用erbB 3特异性抑制erbB 3信号传导, shRNA、抗erbB 3阻断抗体(Ab)或Akt抑制剂增加miR-203和miR-204的水平。 erbB 2+乳腺癌细胞中的542- 3 p。有趣的是,miR-203和miR-542- 3 p都被鉴定为 肿瘤抑制性miRNAs,并且在各种人类中由于启动子甲基化而经常下调, 癌症,包括乳腺癌。生物信息学分析表明miR-203和/或miR-542- 3 p靶向 几个关键基因,包括Survivin、ZEB 1、ZEB 2、Snail 1和/或Slug,负责耐药性, 上皮-间质转化(EMT)和肿瘤转移。我们还发现, ZEB 1、Snail 1、Slug和波形蛋白对erbB 2+乳腺癌细胞中erbB 3异位表达的影响因此我们 假设erbB 3信号传导激活通过以下途径促进erbB 2+乳腺癌转移: 肿瘤抑制性miR-203/miR-542- 3 p的表观遗传沉默和erbB 3的有效抑制 将通过诱导miR-203/miR-542- 3 p显著抑制转移。我们打算定义miR- 203和miR-542- 3 p作为erbB 3信号传导的关键下游介质,以增强肿瘤的转移潜力。 通过上调EMT标志物来抑制erbB 2+乳腺癌细胞;并鉴定抑制erbB 2+乳腺癌细胞的新策略/试剂。 erbB 3通过诱导miR-203/miR-542- 3 p预防或减弱erbB 2+乳腺癌转移。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bolin Liu其他文献

Bolin Liu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bolin Liu', 18)}}的其他基金

HER3-PHF8 signaling axis in triple-negative breast cancer progression
三阴性乳腺癌进展中的 HER3-PHF8 信号轴
  • 批准号:
    10584868
  • 财政年份:
    2022
  • 资助金额:
    $ 35.05万
  • 项目类别:
ErbB3-miRNA axis in tumor metastasis of erbB2-positive breast cancer
erbB2 阳性乳腺癌肿瘤转移中的 ErbB3-miRNA 轴
  • 批准号:
    9174796
  • 财政年份:
    2016
  • 资助金额:
    $ 35.05万
  • 项目类别:
ErbB3-miRNA axis in tumor metastasis of erbB2-positive breast cancer
erbB2 阳性乳腺癌肿瘤转移中的 ErbB3-miRNA 轴
  • 批准号:
    9763330
  • 财政年份:
    2016
  • 资助金额:
    $ 35.05万
  • 项目类别:
Survivin-targeting miRNAs in erbB3 promotion of erbB2-positive breast cancer
生存素靶向 miRNA 在 erbB3 促进 erbB2 阳性乳腺癌中的作用
  • 批准号:
    8621261
  • 财政年份:
    2014
  • 资助金额:
    $ 35.05万
  • 项目类别:
Survivin-targeting miRNAs in erbB3 promotion of erbB2-positive breast cancer
生存素靶向 miRNA 在 erbB3 促进 erbB2 阳性乳腺癌中的作用
  • 批准号:
    8804923
  • 财政年份:
    2014
  • 资助金额:
    $ 35.05万
  • 项目类别:

相似海外基金

Myocardial preconditioning effects of amino acids and PI3K/Akt signaling pathway
氨基酸和PI3K/Akt信号通路的心肌预适应作用
  • 批准号:
    16K10955
  • 财政年份:
    2016
  • 资助金额:
    $ 35.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Myocardial preconditioning effects of high-dose insulin and PI3K/Akt signaling pathway
大剂量胰岛素及PI3K/Akt信号通路对心肌的预处理作用
  • 批准号:
    25462429
  • 财政年份:
    2013
  • 资助金额:
    $ 35.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Functional analysis of the PI3K/Akt signaling pathway during the mammalian inner ear development and its application for regenerative medicine
哺乳动物内耳发育过程中PI3K/Akt信号通路的功能分析及其在再生医学中的应用
  • 批准号:
    23592496
  • 财政年份:
    2011
  • 资助金额:
    $ 35.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Analysis of regulatory mechanism of PI3K-Akt signaling pathway by TTC3
TTC3对PI3K-Akt信号通路的调控机制分析
  • 批准号:
    22770118
  • 财政年份:
    2010
  • 资助金额:
    $ 35.05万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Gq-coupled Receptors Inhibit PI 3-kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
  • 批准号:
    8003647
  • 财政年份:
    2009
  • 资助金额:
    $ 35.05万
  • 项目类别:
Molecular Therapy Targeting PTEN-Akt Signaling Pathway in Prostate Cancer.
前列腺癌中针对 PTEN-Akt 信号通路的分子治疗。
  • 批准号:
    17591697
  • 财政年份:
    2005
  • 资助金额:
    $ 35.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Gq-coupled Receptors Inhibit PI 3-kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
  • 批准号:
    7525551
  • 财政年份:
    2002
  • 资助金额:
    $ 35.05万
  • 项目类别:
Gq-coupled Receptors Inhibit PI 3-kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
  • 批准号:
    7645586
  • 财政年份:
    2002
  • 资助金额:
    $ 35.05万
  • 项目类别:
Gq-Coupled Receptors Inhibit PI 3-Kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
  • 批准号:
    8064263
  • 财政年份:
    2002
  • 资助金额:
    $ 35.05万
  • 项目类别:
Gq-Coupled Receptors Inhibit PI 3-Kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
  • 批准号:
    8274809
  • 财政年份:
    2002
  • 资助金额:
    $ 35.05万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了